Point-of-care molecular diagnostics market seen reaching $12.44 billion by 2035

Market Research Future projects the global point-of-care molecular diagnostics market will rise from $5.06 billion in 2026 to $12.44 billion by 2035, driven by CLIA-waiver expansion, BARDA stockpiling, and broader decentralized testing. The outlook points to faster adoption in hospitals, pharmacies and clinics as rapid sample-to-answer systems replace centralized PCR workflows.

Why it matters: - Point-of-care molecular diagnostics are moving testing closer to patients, which can shorten treatment decisions and shift spending away from centralized reference labs. - Market Research Future forecasts the category will grow at a 10.5% CAGR from 2026 to 2035, reaching $12.44 billion from $5.06 billion in 2026. - The market base was estimated at $4.58 billion in 2025. - Rapid testing matters most in infectious disease care, where turnaround time affects diagnosis, antimicrobial use and patient disposition.

What happened: - Market Research Future published a forecast on Aug. 12, 2026 for the global point-of-care molecular diagnostics market. - The report ties growth to CLIA-waiver expansion, BARDA stockpiling programs and decentralized testing infrastructure. - A free sample and customization request are available, along with the full report.

The details: - Between 2022 and 2024, 14 molecular assays received CLIA-waived status from the U.S. Centers for Medicare & Medicaid Services. - The waiver expansion opens testing in physician offices and retail pharmacies without a laboratory director present. - The U.S. now has more than 220,000 certificate-of-waiver sites. - CMS reimbursement for waived molecular testing ranges from $45 to $142 per test. - BARDA's Rapid Diagnostics for Infectious Disease program could provide $650 million between 2021 and 2025 to firms that can scale cartridge production within 72 hours of a declared public health emergency. - Lyophilized reagents are said to cut cold-chain costs by about 35%. - Cloud-connected instrument dashboards are being used to predict maintenance downtime. - Since 2021, increased competition and procurement guarantees have reduced per-test pricing by about 18%. - CPT codes 87631-87633 encourage emergency departments and urgent-care chains to adopt molecular respiratory panels. - CVS and Walgreens have piloted in-store molecular STI testing in select states. - NHS England's plan to deliver 160 community diagnostic centres by 2025 creates a procurement pipeline exceeding GBP 350 million for rapid molecular platforms. - European antimicrobial-stewardship data show rapid molecular point-of-care testing can reduce inappropriate antibiotic prescriptions by up to 30% and save payers about $2,000 to $5,000 per patient in downstream resistance-management costs.

Between the lines: - The report frames growth as structurally driven, not tied to short-term healthcare spending cycles. - The market is shifting from batch PCR in centralized labs to sample-to-answer cartridge systems that deliver results in under 30 minutes. - That shift favors companies with cartridge supply, analyzer placement and reimbursement access over pure laboratory service models. - Competitive pressure is also rising as patent expirations and generic reagent entry fragment some branded segments. - The market remains concentrated, with the top five companies taking an estimated 60% to 68% of global revenue.

What's next: - Assays and kits should remain the largest revenue segment, with about 79% share in 2025. - Instruments and analyzers are projected to be the fastest-growing product segment at 12.9% CAGR through 2035. - Infectious disease testing is expected to stay the dominant application, with about 74% share in 2025. - Oncology is projected to be the fastest-growing application at 15.2% CAGR as liquid-biopsy companion diagnostics move closer to the bedside. - PCR-based systems are expected to remain the largest technology segment at about 75% share in 2025, while INAAT is projected to grow fastest at 15.1% CAGR. - Hospitals are projected to remain the largest end user at about 59% share in 2025. - North America is expected to hold the largest regional share at about 46.5% in 2025, while Asia-Pacific is projected to grow fastest at 14.2% CAGR. - The Global Fund's 2026-2028 replenishment cycle targets $18 billion in total commitments, with molecular diagnostics listed as a top-three procurement priority. - Start-ups have raised more than $800 million in venture funding for AI-enabled diagnostic decision-support tools since 2023.

The bottom line: - Point-of-care molecular diagnostics are becoming a core part of routine care, and policy, reimbursement and public-health procurement are likely to keep pushing demand higher through 2035.